Ningbo Menovo Pharm Co Ltd
Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company's products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal t… Read more
Ningbo Menovo Pharm Co Ltd (603538) - Net Assets
Latest net assets as of September 2025: CN¥2.42 Billion CNY
Based on the latest financial reports, Ningbo Menovo Pharm Co Ltd (603538) has net assets worth CN¥2.42 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.75 Billion) and total liabilities (CN¥2.33 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.42 Billion |
| % of Total Assets | 50.95% |
| Annual Growth Rate | 14.86% |
| 5-Year Change | 30.01% |
| 10-Year Change | 254.82% |
| Growth Volatility | 13.37 |
Ningbo Menovo Pharm Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Ningbo Menovo Pharm Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ningbo Menovo Pharm Co Ltd (2011–2024)
The table below shows the annual net assets of Ningbo Menovo Pharm Co Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.29 Billion | +4.84% |
| 2023-12-31 | CN¥2.19 Billion | +0.57% |
| 2022-12-31 | CN¥2.17 Billion | +9.84% |
| 2021-12-31 | CN¥1.98 Billion | +12.26% |
| 2020-12-31 | CN¥1.76 Billion | +12.37% |
| 2019-12-31 | CN¥1.57 Billion | +17.04% |
| 2018-12-31 | CN¥1.34 Billion | +15.28% |
| 2017-12-31 | CN¥1.16 Billion | +59.03% |
| 2016-12-31 | CN¥731.02 Million | +13.19% |
| 2015-12-31 | CN¥645.81 Million | +14.44% |
| 2014-12-31 | CN¥564.34 Million | +15.78% |
| 2013-12-31 | CN¥487.44 Million | +10.14% |
| 2012-12-31 | CN¥442.58 Million | +16.94% |
| 2011-12-31 | CN¥378.47 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ningbo Menovo Pharm Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 891.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.27 Billion | 58.06% |
| Common Stock | CN¥218.75 Million | 9.98% |
| Other Components | CN¥700.98 Million | 31.97% |
| Total Equity | CN¥2.19 Billion | 100.00% |
Ningbo Menovo Pharm Co Ltd Competitors by Market Cap
The table below lists competitors of Ningbo Menovo Pharm Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sarkuysan Elektrolitik Bakir Sanayi ve Ticaret AS
IS:SARKY
|
$551.61 Million |
|
Shenzhen Urovo Technology Co Ltd
SHE:300531
|
$551.66 Million |
|
Heiwa Corporation
F:HWC
|
$551.90 Million |
|
Kimball Electronics
NASDAQ:KE
|
$552.44 Million |
|
Metropolis Healthcare Limited
NSE:METROPOLIS
|
$551.52 Million |
|
Genesis Energy Limited
F:1G6
|
$551.46 Million |
|
Advanced Wireless Semiconductor Co
TWO:8086
|
$551.35 Million |
|
Argan SA
PA:ARG
|
$551.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ningbo Menovo Pharm Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,096,251,882 to 2,192,744,591, a change of 96,492,709 (4.6%).
- Net income of 66,806,624 contributed positively to equity growth.
- Dividend payments of 22,711,701 reduced retained earnings.
- Share repurchases of 629,789 reduced equity.
- Other factors increased equity by 53,027,575.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥66.81 Million | +3.05% |
| Dividends Paid | CN¥22.71 Million | -1.04% |
| Share Repurchases | CN¥629.79K | -0.03% |
| Other Changes | CN¥53.03 Million | +2.42% |
| Total Change | CN¥- | 4.60% |
Book Value vs Market Value Analysis
This analysis compares Ningbo Menovo Pharm Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.46x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 10.62x to 2.46x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥2.39 | CN¥25.37 | x |
| 2012-12-31 | CN¥2.79 | CN¥25.37 | x |
| 2013-12-31 | CN¥3.09 | CN¥25.37 | x |
| 2014-12-31 | CN¥3.55 | CN¥25.37 | x |
| 2015-12-31 | CN¥4.07 | CN¥25.37 | x |
| 2016-12-31 | CN¥4.59 | CN¥25.37 | x |
| 2017-12-31 | CN¥5.90 | CN¥25.37 | x |
| 2018-12-31 | CN¥5.87 | CN¥25.37 | x |
| 2019-12-31 | CN¥6.64 | CN¥25.37 | x |
| 2020-12-31 | CN¥7.55 | CN¥25.37 | x |
| 2021-12-31 | CN¥8.09 | CN¥25.37 | x |
| 2022-12-31 | CN¥9.17 | CN¥25.37 | x |
| 2023-12-31 | CN¥9.05 | CN¥25.37 | x |
| 2024-12-31 | CN¥10.30 | CN¥25.37 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ningbo Menovo Pharm Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.87%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 2.12x
- Recent ROE (3.05%) is below the historical average (10.51%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 19.14% | 14.14% | 0.69x | 1.96x | CN¥33.11 Million |
| 2012 | 14.30% | 12.45% | 0.59x | 1.96x | CN¥18.24 Million |
| 2013 | 14.87% | 13.75% | 0.58x | 1.86x | CN¥22.61 Million |
| 2014 | 13.59% | 11.43% | 0.66x | 1.81x | CN¥19.23 Million |
| 2015 | 12.60% | 12.90% | 0.72x | 1.35x | CN¥15.90 Million |
| 2016 | 11.43% | 13.64% | 0.61x | 1.38x | CN¥9.84 Million |
| 2017 | 4.00% | 7.38% | 0.40x | 1.36x | CN¥-66.95 Million |
| 2018 | 8.05% | 11.35% | 0.37x | 1.90x | CN¥-23.37 Million |
| 2019 | 11.06% | 12.79% | 0.45x | 1.92x | CN¥14.49 Million |
| 2020 | 10.05% | 13.07% | 0.39x | 1.97x | CN¥790.70K |
| 2021 | 8.14% | 11.33% | 0.31x | 2.28x | CN¥-32.62 Million |
| 2022 | 16.25% | 23.26% | 0.33x | 2.12x | CN¥130.36 Million |
| 2023 | 0.55% | 0.95% | 0.28x | 2.11x | CN¥-198.04 Million |
| 2024 | 3.05% | 4.87% | 0.30x | 2.12x | CN¥-152.47 Million |
Industry Comparison
This section compares Ningbo Menovo Pharm Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,523,155,599
- Average return on equity (ROE) among peers: -21.03%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ningbo Menovo Pharm Co Ltd (603538) | CN¥2.42 Billion | 19.14% | 0.96x | $551.56 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $52.15 Million | 21.80% | 0.58x | $623.66 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $765.24 Million | 1.30% | 0.72x | $325.92 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $78.32 Million | 0.00% | 1.98x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $1.24 Billion | 8.20% | 0.96x | $1.75 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $38.34 Billion | 14.39% | 0.44x | $5.59 Billion |
| Hainan Haiyao Co Ltd (000566) | $590.38 Million | -258.34% | 9.36x | $713.60 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $184.11 Million | -46.59% | 2.19x | $317.60 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $1.57 Billion | 22.73% | 1.61x | $426.40 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $2.06 Billion | 23.61% | 0.46x | $2.04 Billion |
| Renhe Pharmacy Co Ltd (000650) | $338.74 Million | 2.59% | 1.24x | $777.45 Million |